#clincial research organization | Explore Tumblr posts and blogs

juniperpublishers-endocrinology · 5 years ago

Text

Idiopathic Hypereosinophilic Syndrome: Etiology, Diagnosis, Manifestations and Management- Juniper Publishers

Introduction

Hypereosinophilia is a clincial condition that can classified into secondary, clonal and idiopathic. Secondary hypereosinophilia is caused by tissue helminthic infection, parasitic infestations, atopy, allergic reactions, vasculitis, or drugs like allopurinol and carbamazepine. Clonal hypereosinophilia represents neoplastic proliferation of eosinophils as part of an underlying stem cell-derived myeloid malignancies and can accompany all types of leukemia and lymphoma [1,2]. Idiopathic hypereosinophilic syndrome (IHS) represents a multisystem disorder defined by sustained eosinophilia; 1.5 x 10(9)/L or greater for at least 6 months (a shorter duration is acceptable in the presence of symptoms that require eosinophil-lowering therapy), of an undetectable cause with evidence of organ system dysfunction (cardiovascular system, skin, central and peripheral nervous system, gastrointestinal tract, eyes). Endomyocardial fibrosis is considered the most classic and known complication of prolonged IHS. Further, skin lesions, multiple erythematous indurated plaques, can be the dominating and/or presenting symptom in about 50% of patients [1-5]. Diagnosis of IHS implies that both secondary and clonal eosinophilia have been ruled out as possible diagnoses. For example, the more accurate term to describe eosinophilia associated with clonal or phenotypically abnormal lymphocytes is lymphocytic variant hypereosinophilia, not lymphocytic variant IHS. Further, rare instances of congenital eosinophilia must be considered in pediatric cases [2]. In 1997, it was previously mentioned that over expression of IL-5 in transgenic mice was shown to lead to both peripheral blood eosinophilia and tissue eosinophilia [5]. Later, in 2007, a population of aberrant T cells that secretes interleukin-5 have been identified in a subset of patients, indicating the existence of lymphocyte-mediated hypereosinophilia. Further, the characterization of specific genetic alterations linked to clonal eosinophilia has been achieved. The most frequently encountered genetic aberrancy is the cryptic FIP1-like 1/platelet-derived growth factor receptor alpha (FIP1L1-PDGFRA) fusion transcript, which results in an eosinophilic, myeloproliferative disorder [6]. In addition, Further, BCR-ABL1 was recently suggested to be screened in those patients [7]. It’s noteworthy that manifestations of IHS can be so diverse and may include among others: cholecystitis and recurrent gastroenteritis [8], monoarticularsynovitis with synovial fluid [9], hepatitis and achalasia [10], primary biliary cirrhosis [11], angina pectoris [12], or even chronic orofacial pain and mucosal inflammation [13]. Cotricosteroids are widely used in IHS treatment. Prompt responses usually were observed in patients who received prednisone at a dose of 1mg/kg daily.Hydroxyurea, imatinib, nilotinib, alemtuzumab, and mepolizumab have been also used in corticosteroid-unresponsive or relapsed patients depending on some markers e.g. usage of tyrosine kinase inhibitors in FIP1L1-PDGFRA-positive patients [2,6,14].

For more Journals in Juniper Publishers please click on https://juniperpublishers.com/journals.php

For more articles in Journal of Thyroid Research please click on: https://juniperpublishers.com/jetr/index.php

#juniper publishers #Thyroid #Hormonal Disturbances #Steroids #Adrenals

0 notes

du-lich-saigon · 7 years ago

Text

Leonhardt’s Launchpads Utah Medtech Innovation Accelerator Expands in Salt Lake City

Salt Lake City–Leonhardt’s Launchpads Utah, Inc., an innovation and startup accelerator focused on organ regeneration and recovery technologies, is expanding its research laboratory space and personnel in Salt Lake City, Utah. The company is adding a new dedicated research lab at BioInnovations Gateway and has acquired additional lab research space in Research Park at 417 S. Wakara Way, Suite 3321, Salt Lake City, UT 84108 adjacent to the University of Utah campus. 20 employees and contract researchers will work out of these locations.

This is in addition to office space rented at the C&S Business Incubator and shared lab space previously rented at BioInnovations Gateway. Most of the startups in the innovation accelerator are based on the core IP platform of bioelectric stimulation, micro pumps, endovascular catheters, micro implants and stem cell based organ regeneration compositions.

The company is in the process of launching clinical trials for skin, hair, knees, teeth, diabetic ulcer treatment and heart support in 2018. Eye, brain, liver, kidney, pancreas, breast, aorta, heart, biological pacing and heart valve regeneration technologies are currently in pre-clinical studies in preparation for clinical studies in the future. CancerCell www.cancercellinc.com one of the startups in the accelerator is launching studies in rodents now to test a seven part bioelectric therapy for shrinking cancer tumors without using toxic radiation or chemo therapies. The company has two issued patents in this area already and many more pending. InStim www.instimcell.com has developed a patent pending bioelectric real time treatment for chronic inflammation. PolypStim www.polyp-stim.com is working on technologies intended to shrink polyps, fibroids and cysts and heal associated tissues more rapidly with bioelectric energy. Second Heart Assist, Inc. www.secondheartinc.com is finishing pre-clinical studies with intent to launch clinical trials first in Australia and later in the USA for its circulatory assist support technologies. OrthdodontiCell www.orthodonticell.com is finishing pre-clincial studies with intent to launch clinical trials soon for bioelectric tooth movement acceleration and stabilization, with hope to prove they can safely reduce brace or aligner wearing time by 2/3rds to straighten teeth.

This expansion will increase research and development operations, enabling the company to employ more engineers and biologists, and will provide a foundation to better host visiting research collaborators. Leonhardt inventions – https://patents.justia.com/inventor/howard-j-leonhardt have been used to treat more than 400,000 patients to date and the Leonhardt’s Launchpads Utah team is determined to help build upon Utah’s place on the map already known as leading life science hub.

“Leonhardt’s Launchpads Utah has been operating in the Salt Lake City area since 2015. During that time, we’ve benefited from the amazing talented workforce and first-rate education, research, and healthcare facilities in the area, especially from the University of Utah. After three years we are convinced there may be no better place in the world to build a medical technology enterprise and to do world class research than Utah.” state Howard J. Leonhardt, Executive Chairman & CEO

“We have recruited nearly our entire lab team from graduates of bioengineering, biology or entrepreneurship programs at the University of Utah. They have entered our fast paced research lab running with the skills necessary to help us succeed. We have multiple research initiatives right here in Utah in collaboration with world class researchers at the University of Utah which greatly enhances the communication loop of turning what we learn from early stage tests into continuous product improvements.” stated Dr. Brett Burton, Executive Director of R&D and Startup Launches at Leonhardt’s Launchpads Utah, Inc. a Ph.D. graduate of the U of Utah Bioengineering Program himself.

“Utah is a place were good science, innovative design and quality manufacturing are practiced. We are proud to be growing our presence in this community and look forward to moving forward our multiple research initiatives in collaboration with local scientists, clinicians and partners.” states Dr. Leslie Miller, Chief Medical Officer for Leonhardt’s Launchpads Utah, Inc.

“Leonhardt’s Launchpads Utah, Inc. is the best place to experience an accelerated crash course of the medtech industry for new University of Utah graduates such as myself. From direct hands-on research, to bench-top prototyping, to effective business commercialization and direct communication with the C-suite, Leonhardt’s Launchpads Utah, Inc. is the ideal stimulating experience for career growth with unlimited amounts of exposure that simultaneously fosters learning. With over 20 research projects in various stages of development, the pace is simply astounding. We feel we do more here in a month than many other companies do in a year,” states Kapil K. Sharma, Startup Launch Supervisor & Staff R&D Bioengineer, currently a Professional MBA student, a recent Masters graduate from the Bioengineering BioInnovate program, and the former Co-President of the Bench-to-Bedside Health Entrepreneurship Program all at the University of Utah.

Leonhardt’s Launchpads Utah, Inc. and its Utah based spin out startup Second Heart Assist, Inc. utilize Biomerics a local Utah headquartered contract engineering and OEM manufacturing firm for a number of services for a number of products including heart pacing and infusion leads and circulatory assist pump catheters.

“USTAR, the Governor’s Office of Economic Development, The University of Utah and BioUtah have all been instrumental in fostering our growth in Utah since landing here in 2015. The infrastructure and talent here are outstanding and we believe there may be no better place to grow a medtech company than here.” further stated Howard J. Leonhardt, Executive Chairman & CEO

The grandest long vision project of the team is early stage work to build and test a whole body regeneration chamber – https://vimeo.com/179280204. The accelerator is currently working on a National Science Foundation Small Business Innovation Research (SBIR) grant application with hope to gain seed stage funding for this research.

The innovation and startup accelerator business model is to accelerate each innovation and startup through first-in-man clinical results and then seek out a strategic partner to help develop the product the rest of the way to commercialization.

About Leonhardt’s Launchpads Utah, Inc.:

Founded in 2015 and incorporated in Utah in 2016 an innovation and startup accelerator focused on organ regeneration and recovery technologies primarily based on a core platform of bioelectric stimulators, micro pumps, endovascular catheters, implantable micro devices and stem cell based organ regeneration composition. Web site – https://leonhardtventures.com/leonhardts-launchpads-utah/

About Leonhardt Ventures:

Leonhardt Ventures is the commercialization arm for the inventions of Howard J. Leonhardt and the majority owner of Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. In the 1980’s the team patented and pioneered cardiovascular balloon catheters, in the 1990’s stent grafts and percutaneous heart valves and since 1999 the focus has been on organ regeneration with a combination of bioelectrics and biologics. There are currently 31 startups in the Leonhardt’s Launchpads 2018 portfolio class. Web sites – www.leonhardtventures.com + www.calxstars.com

Selected mentioned startup web sites: www.bioleonhardt.com, www.vascustim.com, ;www.valvublator.com, www.cerebracell.com, www.cancercellinc.com, www.ear-cell.com, ;www.polypstim.com www.kidney-cell.com, www.ortho-stim.com, www.skin-stim.com, ;www.haircellstim.com, www.instimcell.com, www.orthodonticell.com, ;www.dentacellaccelerator.com, https://leonhardtventures.com/aortacell/,https://leonhardtventures.com/bio-pace/ – others may be found at www.leonhardtventures.com

Disclaimer:

All product developments mentioned are early stage and unproven yet to be either safe or effective. Any product performance claims implied are not meant to be absolute or deemed proven via statistically significant and powered evaluations. These are early stage optimistic observations only. The company may not have the resources to fully develop these products. Any patents licensed, issued or pending may not be kept active or held. Any strategic partnerships mentioned may not be maintained. Any forward looking statements may be subject to change forward without notice. The communication reflects the optimism of founders and developers only. As an investment these startups must be considered very high risk not suitable for many and restricted to verified accredited and sophisticated experienced investors only at this time. A substantial portion of the engaged team derives sources of income from other sources and may not be fully focused on accomplishing the goals of the organization which may impede or delay progress.

Source Article

The post Leonhardt’s Launchpads Utah Medtech Innovation Accelerator Expands in Salt Lake City appeared first on D-L-SAIGON.

Learn More At:http://www.du-lich-saigon.com/leonhardts-launchpads-utah-medtech-innovation-accelerator-expands-in-salt-lake-city/

0 notes

apsbicepstraining · 7 years ago

Text

Going the most up to date publication of “Guide To Rational Living” by Dr. Albert EllisThis new technology can help predict if you’re going to die

Want to know if youll be dead in 5 year? Just let a computer look at your organs.

New research have pointed out that future prophesying computers could be coming to infirmaries in the near future. Researchers are hoping that information and communication technologies could be used to predict serious sickness and medical conditions such as heart attacks.

For the study, five yearold medical likeness of 48 patients chests were analyzed by neural networks. From these likeness alone, the organizations of the system was able to predict( with 69 percent accuracy) whether or not a patient would die within five years. It was also able to predict medical outcomes by analyzing large volumes of data and detecting subtle structures. This new exambyAI has proven to be more effective than a physical exam from a doctor, though apparently its truly not a fair fight.

MICROSOFT, OTHERS SPEARHEADING A ‘SMART CITIE’S INITIATIVE FOR EVERYONE

Human doctors are not trained to predict fatality, so the comparing is a bit unfair, study president Dr. Luke OakdenRayner of the University of Adelaide told Fox News. OakdenRayner added that previous investigate exploiting clincial data such as age, fornication or physical fitness had between 65 percentage and 75 percentage accuracy, so the brand-new analyze “compare[ s] favorably, specially considering we excluded factors like age and copulation from our analysis.”

Currently the system is only trained to predict fatality within five years, although, is in accordance with OakdenRayner, with the right dataset it was necessary to inconsequential to extend the technique to other day magnitudes.

To predict mortality at ten years, for example, the system would need to analyze CT scans performed over ten years ago so that OakdenRayners team could have the follow up outcomes. The investigates also couldnt tell what exactly it was personal computers were discovering in the portraits to make their evaluation, even though they did find a strong relationship between the prediction of fatality and the presence of visible maladies such as emphysema and congestive coronary failure.

OakdenRayner has pointed out that certain proficiencies could be applied to visualize how the computers were receiving the checks, but the study was too small to use them this goround.

You can identify the regions of the portraits that contributed to the prediction, and you can hallucinate personas that overdo the features that the system uses( generating exemplars of “survival” and “mortality” searches ), he added. We couldn’t apply these techniques effectively due to our small dataset, but are currently applying them to a much larger group consisting of tens of thousands of patients.

ZAPPING YOUR BRAIN WITH ELECTRICITY CAN AID CREATIVITY — BUT THERE’S A CATCH

For this next round of testing, OakdenRayner and his crew will be incorporating highly predictive clinical knowledge like age and copulation into their examples, which they expect will improve projection accuracy.

Similar medical AI news has been cultivating up lately: a startup in China disclosed an AI system that can help doctors recognize lung cancer by questioning CT scans, and IBM now has AI in infirmaries( called Watson) that can answers patient wonders. Nonetheless, if perfected, this new medical AI could be the most exciting growing yet.

We will start looking at prophesying other medical occasions before they arise, like strokings, cancer and heart attack, OakdenRayner said.

The analyze can be found in “Scientific Reports.”

The post Going the most up to date publication of “Guide To Rational Living” by Dr. Albert EllisThis new technology can help predict if you’re going to die appeared first on apsbicepstraining.com.

from WordPress http://ift.tt/2jaIb48 via IFTTT

#IFTTT #WordPress

0 notes

type2diabetestreatments-blog · 8 years ago

Text

TEDxDelMar: Meeting of the Diabetes Research Minds

New Post has been published on http://type2diabetestreatment.net/diabetes-mellitus/tedxdelmar-meeting-of-the-diabetes-research-minds/

TEDxDelMar: Meeting of the Diabetes Research Minds

This past weekend, 17 of the leading researchers in the diabetes community traveled to San Diego, CA, to speak at TEDxDelMar, an exciting day-long conference focused on the latest breakthroughs and continuing challenges in the search for a cure. Although the cure was the main focus of the day, TEDxDelMar also featured discussions on living well with diabetes (with talks including Dr. Steve Edelman and Dr. Bill Polonsky) and the future of diabetes technology (with an update from Dr. Bruce Buckingham).

If you're unfamiliar with TED, it stands for Technology, Entertainment and Design and is a conference series launched in 1984 with the sole mission of sharing "ideas worth spreading." In recent years, TED has evolved to include TEDx, which are smaller, grassroots events independently planned and organized, following some basic guidelines set out by the larger TED organization. Among those guidelines is the requirement that all the presentations — which are kept to a strict limit of 18 minutes or less — are filmed and made available to an audience of millions. About 100 people attended this event in person.

I was thrilled to have the opportunity to attend and hear from some of the top minds working in the field of diabetes cure research. Here are a few highlights:

- "Pigs rule!" was the mantra of Dr. Bernhard Hering, a researcher the University of Minnesota. Dr. Hering shared that there is strong pre-clincial evidence suggesting that pig islet cells could be even more successful in humans than using actual human islets. One pig islet transplant in the liver of a monkey with diabetes has been successful, and the animal has so far gone 275 days without any evidence of immune attack. They're able to use less potent immuno-suppressant drugs as well, which is also safer, he says.

"This is real. This is important. This could really be turned into a treatment with far-reaching implications," Dr. Hering says.

- After having diabetes for decades, what do you think the odds are that your body is still making beta cells? Probably not very high, right? According to Dr. Peter Butler, director of the Larry Hillblom Islet Research Center at UCLA. There's actually a strong probability that you are still making your own beta cells. They have seen this in mothers with diabetes who suddenly make more beta cells during pregnancy. Scientists are trying to determine whether or not beta cells are actually regenerating, or whether all beta cells are dying when the autoimmune system attacks, and still continue to divide — just not in quantities that are useful to us. Dr. Butler showed evidence that an 82-year-old man was still making his own beta cells, over 50 years after being diagnosed with type 1 diabetes. Wow!

- Dr. Jeffrey Bluestone from UC San Francisco and Dr. Mattias von Herrath from the La Jolla Institute of Immunology both spoke about the role the immune system plays in the onset of diabetes, and also the "re-onset" of diabetes that happens when islet cells are replaced in a person with diabetes. Dr. Bluestone explained that cells from your bone marrow travel to your thymus, where they come out "educated about what they need to fight." Somewhere in there, rogue cells leave the thymus and think that your beta cells are the enemy, causing them to kill off your insulin production. A big question scientists are working on answering is why the thymus or the cells do this, and how to re-train your immune system not to attack the beta cells, but without stopping your immune system from fighting off actual foreign invaders, like the flu. Dr. von Herrath is one of the scientists working on intervening in this process.

I was also very lucky to have a chance to speak with some of the researchers presenting at TEDx, who were kind enough to share some messages about the work they are doing:

youtube

The entire day was incredibly educational and really drove home that while there is so much work to be done, there are also a lot of strides being made in diabetes research. Official videos of the TEDxDelMar event will be available on the TEDxTalks website over the next few weeks, and I highly encourage everyone to watch them!

A great closing thought comes from Dr. Maike Sander, whom we interviewed last fall and who is working on stem cell research:

"It wouldn't be science if we knew exactly how to do it. You know you can get to your goal, but you're not exactly sure how to get there. Take an educated guess and try, and you will hit a roadblock, but you will learn something, so the next time you try, you will go a little further. It will only be a matter of time before we figure out all the steps."

In other words, we'll get there someday... we just need to take it one step at a time.

Disclaimer: Content created by the Diabetes Mine team. For more details click here.

Disclaimer

This content is created for Diabetes Mine, a consumer health blog focused on the diabetes community. The content is not medically reviewed and doesn't adhere to Healthline's editorial guidelines. For more information about Healthline's partnership with Diabetes Mine, please click here.

Type 2 Diabetes Treatment Type 2 Diabetes Diet Diabetes Destroyer Reviews Original Article

0 notes

endesuch · 4 years ago

Text

Goal is to review organize, integrate and evaluate previous research (empirical,

Goal is to review organize, integrate and evaluate previous research (empirical, qualitative, and theoretical) on the following topic. Review post 2000 literature on consulatation as it relates to social justice, advocacy, and consultation. THis is in the mental health field, the class is for a counselor education degree. Licensed Clincial Counselor.

View On WordPress

0 notes

apsbicepstraining · 7 years ago

Text

Going the most up to date publication of “Guide To Rational Living” by Dr. Albert EllisThis new technology can help predict if you’re going to die

Want to know if youll be dead in 5 year? Just let a computer look at your organs.

MICROSOFT, OTHERS SPEARHEADING A ‘SMART CITIE’S INITIATIVE FOR EVERYONE

OakdenRayner has pointed out that certain proficiencies could be applied to visualize how the computers were receiving the checks, but the study was too small to use them this goround.

ZAPPING YOUR BRAIN WITH ELECTRICITY CAN AID CREATIVITY — BUT THERE’S A CATCH

We will start looking at prophesying other medical occasions before they arise, like strokings, cancer and heart attack, OakdenRayner said.

The analyze can be found in “Scientific Reports.”

from WordPress http://ift.tt/2jaIb48 via IFTTT

#IFTTT #WordPress

0 notes